Sacituzumab
As of the edition of 20 October 2026, Sacituzumab is an antibody: marketed, first approved in 2021 (CH); acts on TACSTD2 and TOP1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Antibody
- Brand name
- Trodelvy
- First approved
- 9 September 2021 (CH)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Gilead Sciences Switzerland Sàrl
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 2 |